Every Form 4 that ProQR Therapeutics N.V. (PRQR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PRQR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PRQR filings page.
ProQR Therapeutics N.V. reports that Chief Executive Officer Daniel Anton de Boer purchased 200,000 Ordinary Shares on 2026-07-31 at $1.7698 per share in a transaction described as a purchase in open market or private transaction, increasing his direct holdings to 500,000 shares. The Rule 10b5-1 trading-plan checkbox was not marked for this transaction.
ProQR Therapeutics N.V. director Bart Filius purchased 150,000 Ordinary Shares on July 17, 2026 at $1.7195 per share in a transaction described as a purchase in the open market or a private transaction. After this trade, he directly holds 300,000 Ordinary Shares of the company.
ProQR Therapeutics N.V. Chief Executive Officer Daniel Anton de Boer reported an open-market purchase of 150,000 Ordinary Shares of the company on 9 July 2026 at a price of $1.74 per share. Following this transaction, he directly holds 300,000 Ordinary Shares of ProQR Therapeutics.
ProQR Therapeutics N.V. reported that Chief Executive Officer Daniel Anton de Boer bought Ordinary Shares in the company. On July 7, 2026, he made an open-market purchase of 150,000 Ordinary Shares at $1.59 per share. After this transaction, he directly owns 150,000 Ordinary Shares, indicating this was a new position or a reset position as reflected in this filing.
ProQR Therapeutics N.V. director Hinsch Gylvin Lykke received a grant of share options covering 14,595 Ordinary Shares. The options have an exercise price of $1.42 per share, based on the closing market price of the company’s ordinary shares on June 1, 2026.
The options were granted on June 2, 2026, with 25% of the underlying shares vesting and becoming exercisable on June 2, 2027. The remaining 75% vest in 12 substantially equal quarterly installments thereafter, contingent on Lykke’s continued service with ProQR.
ProQR Therapeutics N.V. director Bart Filius reported an open-market purchase of Ordinary Shares. On the reported date, he bought 150,000 Ordinary Shares at a price of $1.54 per share. Following this transaction, his directly held position in ProQR totals 150,000 Ordinary Shares.
ProQR Therapeutics N.V. director Hinsch Gylvin Lykke received a grant of options to buy 14,495 ordinary shares. These share options have an exercise price of $1.42 per share and expire on June 1, 2036, functioning as equity-based compensation rather than an open-market trade.
According to the vesting terms, 25% of the options vest and become exercisable on June 2, 2027, with the remaining 75% vesting in 12 substantially equal quarterly installments thereafter, contingent on continuous service. After this grant, the filing shows 14,495 derivative securities held.